Dechra Pharmaceuticals PLC (DPH.L)
DPH.L on London Stock Exchange
Change (% chg)
|2016||Non-Executive Chairman of the Board|
|2001||Chief Executive Officer, Executive Director|
|2019||Acting Chief Financial Officer, Executive Director|
|2015||President, North America|
|2012||Managing Director - Dechra Veterinary Products Europe, Executive Director|
|2014||Group HR Director|
|57||2018||Dechra Veterinary Products International Group Director|
|2019||Group Manufacturing and Supply Director|
|2015||Regulatory Affairs and Business Development Group Director|
|2016||Group Product Development Director|
|2012||Group IT Director|
|62||2013||Independent Non-Executive Director|
|60||2016||Non-Executive Independent Director|
|58||2013||Senior Independent Non-Executive Director|
|Mr. Tony Rice is an Non-Executive Chairman of the Board of the Company. Tony joined the Board in May 2016 and was appointed Chairman in October 2016. He served as Chief Executive Officer at Cable & Wireless and Tunstall Holdings, and prior to that held various roles at BAE Systems including Managing Director of Commercial Aircraft and Group Managing Director of Business Development. He has also served as a Non-Executive Director at Punch Taverns, Spirit Pub Company, Cable & Wireless, Telewest Communications and Saab Technologies, and Chairman of Alexander Mann Solutions. Tony is currently the Senior Independent Non-Executive Director and Chairman of the Remuneration Committee at Halma plc.|
|Mr. Ian David Page is a Chief Executive Officer, Executive Director of Dechra Pharmaceuticals PLC. Ian has gained detailed knowledge and experience through various positions he has held within the pharmaceutical and veterinary arena. He has a solid understanding of business development both in the UK and globally. In particular he has extensive experience in M&A and in the successful delivery of strategic plans. Ian joined NVS, Dechra’s former services business, at its formation in 1989 and was an integral part of the management buyout in 1997, becoming its Managing Director in 1998. He joined the Board in 1997 and became Chief Executive Officer in 2001. Ian has played a key role in the development of the Group’s growth strategy.|
|Mr. Paul Sandland, MAAT, FCCA, is Acting Chief Financial Officer, Executive Director of the Company. He was appointed as Group Financial Controller of Dechra and Finance Director of Dechra Laboratory Services and Dechra Specialist Laboratories in January 2010. He qualified as a Chartered Certified Accountant in 2005. Paul spent five years post qualification at KPMG, during which time he was part of the team which advised the Group on its acquisition of VetXX in 2008.|
|Mr. Mike Eldred, BA, MBA is a President, North America of Dechra Pharmaceuticals PLC. Mike joined Dechra in 2004 and is responsible for Dechra Veterinary Products’ North American business. Mike has more than 20 years’ experience in the animal health sector, having held senior positions in business development, sales and operations at Virbac Corporation, Fort Dodge Animal Health and Sanofi Animal Health. As our first employee in the US, he has built the US and Canadian team to 169 people and with a strong Dechra culture has grown sales revenue to £148.4 million. Mike has also been involved in several commercial agreements and acquisitions for the Group including Pharmaderm, DermaPet, Phycox Animal Health and Putney. Mike has a BA in Business, and an MBA. He is located in Kansas, USA.|
|Mr. Anthony Gerard Griffin is a Managing Director - Dechra Veterinary Products Europe, Executive Director of Dechra Pharmaceuticals PLC. Tony has over 30 years’ experience in the animal health business and has substantial international experience as a result of living and working outside the UK since 1993. He gained broad experience of running an international animal health business with teams in different European countries as Chief Executive Officer of the AUV Group. Tony is the Board nominated Director responsible for health, safety and environmental matters. Tony was appointed Managing Director of DVP EU in May 2012 following the acquisition of Eurovet Animal Health BV from AUV Holding B.V. He joined the AUV Group in 1993 as Director of Exports, having previously worked at Norbrook Laboratories and Moy Park. Tony was promoted to Managing Director of Eurovet in 1996, becoming the Chief Executive Officer of the AUV Group in 2006.|
|Ms. Katy Clough is a Group HR Director of Dechra Pharmaceuticals PLC. Katy joined in April 2014 from AppSense Ltd where she was the Vice President of HR Europe and Rest of the World. With over 15 years operating at Director level within Software, Health, Travel and Finance industries, Katy brings with her a wealth of HR expertise gained in both blue chip corporates and smaller entrepreneurial companies. She has strong international, leadership and M&A experience and has taken responsibility for driving the global people agenda for the Dechra Group. She is located at Head Office, Northwich, UK.|
|Mr. Giles Coley is Dechra Veterinary Products International Group Director of the Company. Giles joined Dechra in January 1999 as sales and marketing manager for Arnolds Veterinary Products having previously spent 14 years primarily involved in dairy farming business consultancy. During his time at Dechra he has been responsible for the launch and market development of our leading brand Vetoryl, as well as a number of our other key brands. Giles has also been an integral member of the teams that ensured fast and smooth integrations of several of our acquisitions and in particular as lead in the integration of Apex in 2016. In his role of Dechra Veterinary Products International Group Director, his responsibilities are extremely varied and involve managing and growing our existing business through Apex and distribution partners, as well as further developing our Dechra International strategy through product registrations and market development. Giles has a BSc degree in Agricultural Technology. He is located in Sansaw, UK.|
|Mr. Simon Francis is Group Manufacturing and Supply Director of the Company. He has over 20 years of experience working in a variety of challenging and senior roles within the Pharmaceutical industry. Simon started his career with Bayer Pharmaceuticals in Quality Control (QC) after completing a chemistry degree at Swansea University. He continued to take on a variety of roles within quality, supply chain, production and other operational roles within pharmaceutical companies (Patheon and Boehringer Ingelheim) across sites in the UK, before moving to China for five years to take up the site head role with Boehringer Ingelheim in Shanghai. This was followed by a move to the Boehringer Ingelheim headquarters in Germany, before taking on the Managing Director/Site Head role for Sandoz (Novartis) covering three generic manufacturing sites based out of Magdeburg, Germany. For the last two years, Simon has been based in Switzerland as the Head of Strategy Global Solids for Novartis and as part of the Senior Executive Team, responsible for product strategy, supply chain and product lifecycle across 35 manufacturing sites. Within these roles Simon has also led significant strategic projects around M & A, global ERP implementations, tech transfers and site transformations. As the Group Manufacturing and Supply Director, Simon is responsible for people across our manufacturing sites in Europe namely Bladel, the Netherlands; Zagreb, Croatia; Melbourne, USA; and Skipton, UK.|
|Dr. Susan Longhofer, DVM, MS, DipACVIM, is a Regulatory Affairs and Business Development Group Director of Dechra Pharmaceuticals PLC. Susan joined the Group in June 2005. A veterinarian with over 26 years’ experience in the industry, she leads a team of approximately 50 staff around the globe responsible for registering new products and maintaining the registrations of our existing products. She has recently assumed a Business Development role searching out new products to continue to fill our product development pipeline. Prior to joining Dechra, Susan worked for Virbac Corporation, Heska Corporation and Merck Research Laboratories. Susan holds an MS and a DVM in Veterinary Science and is a Diplomate, American College of Veterinary Internal Medicine. She is located in Kansas, USA.|
|Dr. Anthony Lucas is Group Product Development Director of the Company. Anthony joined Dechra in 2016 following the acquisition of Putney Inc. where he was Senior Vice President of R&D. Anthony is originally a veterinarian from Australia with five years in clinical practice including a residency in emergency and critical care. Following a Masters in veterinary pharmacology, PhD in human pharmacology and post-doc at the University of Kansas, he spent six years at Elanco in early drug development, technology acquisition and as a Six Sigma blackbelt. In his six years at Putney, Anthony built the R&D team, which delivered ten FDA product approvals. As the Group Product Development Director, Anthony leads a team of 50 scientists across five global research centres, to efficiently deliver the pipeline of products to meet Dechra’s growth needs. He is located in Maine, USA.|
|Mr. Allen Mellor is a Group IT Director of Dechra Pharmaceuticals PLC. Allen joined the Dechra in April 2012 and has developed and implemented the Group IT strategy during this time. During the last 20 years, Allen has gained a breadth of experience from the implementation of diverse business solutions across multiple industry sectors including Justice, Education, Energy, Distribution and Retail. Having held several senior management positions encompassing software development, IT service provision and IT departmental management, his last role was as Head of IT for the BSS Group PLC, a leading plumbing and heating distribution company. Allen is currently responsible for all Group IT support to a multitude of internal customers. He is located at Head Office, Northwich, UK.|
|Ms. Melanie Hall is Secretary of the Company. Melanie joined Dechra in January 2010 as the Assistant Company Secretary, and was promoted to Deputy Company Secretary in May 2015 and Company Secretary in July 2017. Prior to joining Dechra she has gained over 25 years’ experience in various company secretarial roles including at GKN plc, TRW Automotive Inc and Pendragon PLC. Melanie is a Fellow of the Institute of Chartered Secretaries and Administrators. She is located at the Head Office, Northwich, UK.|
|Ms. Lisa Bright is Non-Executive Director of the Company. Lisa is currently President International, and previously Chief Commercial and Corporate Affairs Officer of Intercept Pharmaceuticals, Inc, a global biopharmaceutical company focused on the development and commercialisation of novel therapeutics. Previously Lisa held various Vice President roles at Gilead Sciences, Inc and GlaxoSmithKline plc, in Regional General Management, Government Affairs, and sales and marketing. Lisa is also a Non-Executive Director at Ascendis Pharma.|
|Mr. Julian Spenser Heslop is Independent Non-Executive Director of Dechra Pharmaceuticals PLC. Julian joined the Board in January 2013. He served as Chief Financial Officer of GlaxoSmithKline PLC between 2005 and 2011, having previously been appointed its Senior Vice President, Operations Controller between 2001 and 2005 and as Financial Controller of Glaxo Wellcome PLC between 1998 and 2000. Prior to this, Julian held senior finance roles at Grand Metropolitan PLC and Imperial Brewing and Leisure. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Julian is a Non-Executive Director at Itaconix PLC (appointed July 2012) and is their Audit Committee Chairman. He is also a Director of the Royal Academy of Arts (appointed October 2012).|
|Dr. Lawson Macartney, Ph.D. is Non-Executive Independent Director of the Company. He served as Chief Executive Officer of Ambrx Inc. between 2013 and 2015, and prior to that led emerging business for Shire PLC. Before joining Shire in 2011, he was with GlaxoSmithKline PLC (GSK) from 1999 to 2011 in positions of increasing seniority. His final role at GSK was to lead the strategic marketing, outcomes and reimbursement, project management and portfolio teams. In addition to his veterinary degree, Lawson has a PhD in viral pathobiology and is a pathologist, holding Fellowship of the Royal College of Pathologists as well as Membership of the Royal College of Veterinary Surgeons. Lawson has been the Chairman of Viking Therapeutics Inc. since 2015, as well as the Chairman of the Nomination and Corporate Governance and a member of the Audit Committee. He is also a strategic adviser to several investment and private equity groups in both Europe and USA.|
|Ms. Ishbel J. S. Macpherson is an Senior Independent Non-Executive Director of Dechra Pharmaceuticals PLC. Ishbel joined the Group as a Non-Executive Director in February 2013. Prior to this she was Head of UK Emerging Companies Corporate Finance at Dresdner Kleinwort Benson from 1999 to 2005, having previously worked at Hoare Govett and Barclays de Zoete Wedd. Ishbel is Senior Independent Director at Bonmarche Holdings plc (appointed October 2013) and Non-Executive Director of Lloyd’s Register Group Limited (appointed August 2018).|
|Name||Fiscal Year Total|
As Of 30 Jun 2018
- 4 perfect stocks for 'Brexit Britain'!
- Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after today's updates?
- Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra Pharmaceuticals plc today?
- Should You Buy Dechra Pharmaceuticals plc, Enquest Plc & Cairn Energy PLC Today?
- Are GlaxoSmithKline plc, Dechra Pharmaceuticals plc & CareTech Holdings plc On The Cusp Of Stunning Returns?
- 4 Great Growth Picks For 2016 And Beyond: Barclays PLC, Dechra Pharmaceuticals plc, Britvic Plc And Marks & Spencer Group Plc